Mark J. Foley - Jan 31, 2024 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role: CEO, Director
Signature: /s/ Dwight Moxie, Attorney-in-Fact
Stock symbol: RVNC
Transactions as of: Jan 31, 2024
Transactions value $: $0
Form type: 4
Date filed: 2/2/2024, 04:45 PM
Previous filing: Jan 3, 2024
Next filing: Feb 26, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RVNC	Performance Stock Units	Award	$0	+1.07 M		$0.00	1.07 M	Jan 31, 2024	Common Stock	1.07 M		Direct	F1, F2

Explanation of Responses:

Id	Content
F1	The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with the Company through the vesting dates.
F2	The number of securities reported represents the maximum shares that can be earned.

Content

The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with the Company through the vesting dates.

The number of securities reported represents the maximum shares that can be earned.